News
-
-
-
COMMUNIQUÉ DE PRESSE
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
BioVersys AG reports corporate highlights and financial results for the full year 2025, including significant progress in clinical and regulatory advancements of antibacterial products for MDR bacteria -
COMMUNIQUÉ DE PRESSE
Blue Cap AG publishes preliminary financial figures for 2025: successful financial year 2025
Blue Cap AG reports successful financial year 2025 with EUR 129.1 million revenue and 5.5% adjusted EBITDA margin. Focus on Industrials and Business Services segments. Forecast for 2026 remains stable -
COMMUNIQUÉ DE PRESSE
Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
Newron Pharmaceuticals S.p.A. announces nominations for new Board members and resignations of current members ahead of its Annual General Meeting. Full agenda to be released on March 24, 2026 -
-
COMMUNIQUÉ RÉGLEMENTÉ
Mersen : Performance résiliente en 2025, retour attendu de la croissance en 2026
Mersen affiche une performance résiliente en 2025 avec un chiffre d'affaires de 1 186 M€, une marge d'EBITDA maintenue à 16% et un retour anticipé au free cash-flow positif. Objectifs 2026 : croissance organique et marge EBITDA autour de 16% -
COMMUNIQUÉ DE PRESSE
2025 annual results: strong improvement in financial earnings and cash-flows
Exail Technologies achieved significant financial growth in 2025 with record order intake of €844 million (+87%), revenue growth of +28%, and strengthened balance sheet post fundraising of €300 million. Operational milestones include delivering mine countermeasures to navies and increasing production capacity for navigation systems -
COMMUNIQUÉ DE PRESSE
Résultats annuels 2025 : forte amélioration des résultats et des flux de trésorerie
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglustat receives Breakthrough Therapy designation in the US for type 3 Gaucher disease, a rare lysosomal storage disorder. Positive results from the LEAP2MONO study show significant improvements in neurological symptoms
